Allarity Therapeutics (NASDAQ:ALLR) Releases FY 2026 Earnings Guidance

Allarity Therapeutics (NASDAQ:ALLR) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of -0.760–0.730 for the period, compared to the consensus EPS estimate of -0.800. Allarity Therapeutics also updated its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Price Performance

NASDAQ ALLR opened at $0.91 on Friday. The stock has a fifty day moving average of $1.02 and a 200-day moving average of $1.21. Allarity Therapeutics has a 52 week low of $0.77 and a 52 week high of $1.84.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Friday, November 13th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.18). The firm had revenue of $0.01 million during the quarter. Allarity Therapeutics has set its FY 2026 guidance at -0.760–0.730 EPS and its Q4 2026 guidance at 0.010-0.040 EPS. On average, sell-side analysts anticipate that Allarity Therapeutics will post -0.80 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.